You are not logged in.

Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.

Cullinane, Carleen, Dorow, Donna S., Jackson, Susan, Solomon, Benjamin, Bogatyreva, Ekaterina, Binns, David, Young, Richard, Arango, Maria E., Christensen, James G., McArthur, Grant A. and Hicks, Rodney J. 2011, Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models., Journal of nuclear medicine, vol. 52, no. 8, pp. 1261-1267, doi: 10.2967/jnumed.110.086967.

Attached Files
Name Description MIMEType Size Downloads

Title Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
Author(s) Cullinane, Carleen
Dorow, Donna S.
Jackson, Susan
Solomon, Benjamin
Bogatyreva, Ekaterina
Binns, David
Young, Richard
Arango, Maria E.
Christensen, James G.
McArthur, Grant A.
Hicks, Rodney J.
Journal name Journal of nuclear medicine
Volume number 52
Issue number 8
Start page 1261
End page 1267
Total pages 7
Publisher Society of Nuclear Medicine
Place of publication Chicago, Il.
Publication date 2011-08-01
ISSN 1535-5667
Summary The ability of PET to image functional changes in tumors is increasingly being used to evaluate response and predict clinical benefit to conventional and novel cancer therapies. Although the use of (18)F-FDG PET is well established, 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET has potential advantages as a more specific marker of cellular proliferation. c-MET signaling is frequently dysregulated in cancer and is therefore an attractive therapeutic target. Crizotinib (PF-2341066) is a novel adenosine triphosphate-competitive c-MET kinase inhibitor with antitumor activity in a range of tumor models. The aim of this study was to investigate the utility of PET of glucose metabolism and cell proliferation to monitor tumor response to crizotinib in 2 cell lines with aberrant c-MET signaling.
Language eng
DOI 10.2967/jnumed.110.086967
Field of Research 119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2011, Society of Nuclear Medicine
Persistent URL http://hdl.handle.net/10536/DRO/DU:30064319

Document type: Journal Article
Collection: School of Health and Social Development
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 22 times in TR Web of Science
Scopus Citation Count Cited 26 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 36 Abstract Views, 2 File Downloads  -  Detailed Statistics
Created: Fri, 13 Jun 2014, 12:00:41 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.